MindWalk Holdings HYFT
NASDAQ HYFT
$1.32 -0.01 (-0.75%)
As of: Sep 4, 2026 · 11:47 AM EDT

MindWalk Holdings (HYFT) Cost of Revenue (2020 - 2026)

MindWalk Holdings (HYFT) posted quarterly Cost of Revenue of $1.2 billion for Q2 2026, up 50185807.77% year-over-year from N/an in Q2 2025, and up 96817640414.14% quarter-over-quarter from $1.22 in Q1 2026.

Analysis

MindWalk Holdings (HYFT) Cost of Revenue (2020 - 2026) Analysis & Trends

MindWalk Holdings (HYFT) has reported Cost of Revenue for 7 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

  • In Q2 2026, Cost of Revenue rose 50185807.77% year-over-year to $1.2 billion; the TTM figure through Apr 2026 stood at $1.2 billion (up 43570.99% YoY), while the FY2026 annual figure was $4.7 million, up 33.07% from the prior year.
  • Cost of Revenue rose to $1.2 billion in Q2 2026 per HYFT's latest filing, from $1.22 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.2 billion in Q2 2026 and bottomed at -$2.2 million in Q2 2024.
  • Historically, Cost of Revenue has averaged $66.6 million across 5 years, with a median of $1.4 million in 2025.
  • Annual changes were most pronounced in 2024 — Cost of Revenue sank 228.11% — and 2026, when it surged 50185807.77%.
  • MindWalk Holdings' Cost of Revenue stood at $1.8 million in 2022, then tumbled by 99.87% to $2357.0 in 2023, then surged by 40599.44% to $959298.2 in 2024, then advanced by 9.86% to $1.1 million in 2025, then surged by 112033.18% to $1.2 billion in 2026.
  • Business Quant data shows HYFT's Cost of Revenue at $1.2 billion in Q2 2026, $1.22 in Q1 2026, and $1.1 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Vertex Pharmaceuticals 140.21 Bn 132.36 Bn 2.84 Bn 489.20 Mn
2 Regeneron Pharmaceuticals 86.04 Bn 78.05 Bn 3.93 Bn 360.70 Mn
3 Argenx Se 63.73 Bn 58.55 Bn 1.37 Bn 145.00 Mn
4 Moderna 57.59 Bn 52.46 Bn 52.00 Mn 93.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn - -
6 BeOne Medicines 40.13 Bn 35.04 Bn 1.53 Bn 174.53 Mn
7 Alnylam Pharmaceuticals 35.55 Bn 32.24 Bn 992.69 Mn 298.26 Mn
8 Royalty Pharma 28.60 Bn 27.77 Bn - -
9 Insmed 27.70 Bn 26.54 Bn 358.27 Mn 67.21 Mn
10 MindWalk Holdings 61.22 Mn 52.95 Mn 1.82 Mn 1.18 Mn
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2026 1.18 Mn
Jan 31, 2026 1.22 Mn
Oct 31, 2025 1.05 Mn
Jul 31, 2025 1.19 Mn
Apr 30, 2025 2.35 Mn
Jan 31, 2025 681,180.77
Oct 31, 2024 959,298.20
Jul 31, 2024 1.07 Bn
Apr 30, 2024 -2.16 Mn
Jan 31, 2024 2.24 Mn
Oct 31, 2023 2.36 Mn
Jul 31, 2023 2.17 Mn
Apr 30, 2023 1.69 Mn
Jan 31, 2023 1.64 Mn
Oct 31, 2022 1.81 Mn
Jul 31, 2022 1.72 Mn
Apr 30, 2022 1.66 Mn
Jan 31, 2022 1.76 Mn
Oct 31, 2021 1.71 Mn
Jul 31, 2021 1.69 Mn